.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX36_Oblimersen.Oblimersen .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX36_Oblimersen.Oblimersen| name: | Oblimersen | |
| ATC code: | L01XX36 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 7 | mg |
| volume of distribution: | 10.2 | L |
| clearance: | 1.52 | L/h |
| other parameters in model implementation | ||
Oblimersen is an antisense oligonucleotide designed to target the messenger RNA of the BCL-2 protein, inducing apoptosis in tumor cells by reducing BCL-2 expression. Investigated in several cancers, especially chronic lymphocytic leukemia and melanoma, oblimersen has not gained regulatory approval and is not currently in widespread clinical use.
Pharmacokinetic parameters estimated from literature, typical oncology intravenous dosing in adults; population: adult cancer patients.